282 related articles for article (PubMed ID: 25825443)
1. Newly recruited CD11b+, GR-1+, Ly6C(high) myeloid cells augment tumor-associated immunosuppression immediately following the therapeutic administration of oncolytic reovirus.
Clements DR; Sterea AM; Kim Y; Helson E; Dean CA; Nunokawa A; Coyle KM; Sharif T; Marcato P; Gujar SA; Lee PW
J Immunol; 2015 May; 194(9):4397-412. PubMed ID: 25825443
[TBL] [Abstract][Full Text] [Related]
2. Immature myeloid Gr-1+ CD11b+ cells from lipopolysaccharide-immunosuppressed mice acquire inhibitory activity in the bone marrow and migrate to lymph nodes to exert their suppressive function.
Landoni VI; Martire-Greco D; Rodriguez-Rodrigues N; Chiarella P; Schierloh P; Isturiz MA; Fernández GC
Clin Sci (Lond); 2016 Feb; 130(4):259-71. PubMed ID: 26582821
[TBL] [Abstract][Full Text] [Related]
3. Role of Myeloid Cells in Oncolytic Reovirus-Based Cancer Therapy.
Kumar V; Giacomantonio MA; Gujar S
Viruses; 2021 Apr; 13(4):. PubMed ID: 33920168
[TBL] [Abstract][Full Text] [Related]
4. Myeloid-derived suppressor cell activation by combined LPS and IFN-gamma treatment impairs DC development.
Greifenberg V; Ribechini E; Rössner S; Lutz MB
Eur J Immunol; 2009 Oct; 39(10):2865-76. PubMed ID: 19637228
[TBL] [Abstract][Full Text] [Related]
5. SSC(high)CD11b(high)Ly-6C(high)Ly-6G(low) myeloid cells curtail CD4 T cell response by inducible nitric oxide synthase in murine hepatitis.
Zhu K; Zhang N; Guo N; Yang J; Wang J; Yang C; Yang C; Zhu L; Xu C; Deng Q; Zhu R; Wang H; Chen X; Shi Y; Li Y; Leng Q
Int J Biochem Cell Biol; 2014 Sep; 54():89-97. PubMed ID: 25035167
[TBL] [Abstract][Full Text] [Related]
6. Tumor-conditioned Gr-1(+)CD11b(+) myeloid cells induce angiogenesis through the synergistic action of CCL2 and CXCL16 in vitro.
Han EC; Lee J; Ryu SW; Choi C
Biochem Biophys Res Commun; 2014 Jan; 443(4):1218-25. PubMed ID: 24388986
[TBL] [Abstract][Full Text] [Related]
7. Expansion of CD11b(+)Ly6G (+)Ly6C (int) cells driven by medroxyprogesterone acetate in mice bearing breast tumors restrains NK cell effector functions.
Spallanzani RG; Dalotto-Moreno T; Raffo Iraolagoitia XL; Ziblat A; Domaica CI; Avila DE; Rossi LE; Fuertes MB; Battistone MA; Rabinovich GA; Salatino M; Zwirner NW
Cancer Immunol Immunother; 2013 Dec; 62(12):1781-95. PubMed ID: 24114144
[TBL] [Abstract][Full Text] [Related]
8. Hierarchy of immunosuppressive strength among myeloid-derived suppressor cell subsets is determined by GM-CSF.
Dolcetti L; Peranzoni E; Ugel S; Marigo I; Fernandez Gomez A; Mesa C; Geilich M; Winkels G; Traggiai E; Casati A; Grassi F; Bronte V
Eur J Immunol; 2010 Jan; 40(1):22-35. PubMed ID: 19941314
[TBL] [Abstract][Full Text] [Related]
9. Reovirus virotherapy overrides tumor antigen presentation evasion and promotes protective antitumor immunity.
Gujar SA; Marcato P; Pan D; Lee PW
Mol Cancer Ther; 2010 Nov; 9(11):2924-33. PubMed ID: 20978162
[TBL] [Abstract][Full Text] [Related]
10. Identification of myeloid-derived suppressor cells and T regulatory cells in lung microenvironment after Urethane-induced lung tumor.
Rosin FC; Pedregosa JF; de Almeida JS; Bueno V
Int Immunopharmacol; 2011 Jul; 11(7):873-8. PubMed ID: 21238620
[TBL] [Abstract][Full Text] [Related]
11. Dexamethasone inhibits in vivo tumor growth by the alteration of bone marrow CD11b⁺ myeloid cells.
Moon EY; Ryu YK; Lee GH
Int Immunopharmacol; 2014 Aug; 21(2):494-500. PubMed ID: 24953854
[TBL] [Abstract][Full Text] [Related]
12. IFN-γ differentially regulates subsets of Gr-1(+)CD11b(+) myeloid cells in chronic inflammation.
Zhan X; Fang Y; Hu S; Wu Y; Yang K; Liao C; Zhang Y; Huang X; Wu M
Mol Immunol; 2015 Aug; 66(2):451-62. PubMed ID: 26021804
[TBL] [Abstract][Full Text] [Related]
13. Myeloid-derived suppressor cell functionality and interaction with Leishmania major parasites differ in C57BL/6 and BALB/c mice.
Schmid M; Zimara N; Wege AK; Ritter U
Eur J Immunol; 2014 Nov; 44(11):3295-306. PubMed ID: 25142017
[TBL] [Abstract][Full Text] [Related]
14. Polysaccharide Agaricus blazei Murill stimulates myeloid derived suppressor cell differentiation from M2 to M1 type, which mediates inhibition of tumour immune-evasion via the Toll-like receptor 2 pathway.
Liu Y; Zhang L; Zhu X; Wang Y; Liu W; Gong W
Immunology; 2015 Nov; 146(3):379-91. PubMed ID: 26194418
[TBL] [Abstract][Full Text] [Related]
15. Tumor microenvironmental conversion of natural killer cells into myeloid-derived suppressor cells.
Park YJ; Song B; Kim YS; Kim EK; Lee JM; Lee GE; Kim JO; Kim YJ; Chang WS; Kang CY
Cancer Res; 2013 Sep; 73(18):5669-81. PubMed ID: 23867469
[TBL] [Abstract][Full Text] [Related]
16. CD80 in immune suppression by mouse ovarian carcinoma-associated Gr-1+CD11b+ myeloid cells.
Yang R; Cai Z; Zhang Y; Yutzy WH; Roby KF; Roden RB
Cancer Res; 2006 Jul; 66(13):6807-15. PubMed ID: 16818658
[TBL] [Abstract][Full Text] [Related]
17. Tumor-induced myeloid-derived suppressor cell subsets exert either inhibitory or stimulatory effects on distinct CD8+ T-cell activation events.
Schouppe E; Mommer C; Movahedi K; Laoui D; Morias Y; Gysemans C; Luyckx A; De Baetselier P; Van Ginderachter JA
Eur J Immunol; 2013 Nov; 43(11):2930-42. PubMed ID: 23878002
[TBL] [Abstract][Full Text] [Related]
18. VEGF blockade enables oncolytic cancer virotherapy in part by modulating intratumoral myeloid cells.
Currier MA; Eshun FK; Sholl A; Chernoguz A; Crawford K; Divanovic S; Boon L; Goins WF; Frischer JS; Collins MH; Leddon JL; Baird WH; Haseley A; Streby KA; Wang PY; Hendrickson BW; Brekken RA; Kaur B; Hildeman D; Cripe TP
Mol Ther; 2013 May; 21(5):1014-23. PubMed ID: 23481323
[TBL] [Abstract][Full Text] [Related]
19. CD11b+ Ly6Chi Ly6G- immature myeloid cells recruited in response to Salmonella enterica serovar Typhimurium infection exhibit protective and immunosuppressive properties.
Tam JW; Kullas AL; Mena P; Bliska JB; van der Velden AW
Infect Immun; 2014 Jun; 82(6):2606-14. PubMed ID: 24711563
[TBL] [Abstract][Full Text] [Related]
20. Cytokine conditioning enhances systemic delivery and therapy of an oncolytic virus.
Ilett E; Kottke T; Donnelly O; Thompson J; Willmon C; Diaz R; Zaidi S; Coffey M; Selby P; Harrington K; Pandha H; Melcher A; Vile R
Mol Ther; 2014 Oct; 22(10):1851-63. PubMed ID: 24957982
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
